aripiprazole lauroxil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| psychotropics, phenylpiperazine derivatives | 5052 | 1259305-29-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
prodrug of aripiprazole, following intramuscular injection is converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole which is then hydrolyzed to aripiprazole
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 5, 2015 | FDA | ALKERMES |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Needle issue | 476.68 | 45.15 | 103 | 2223 | 10273 | 63476423 |
| Off label use | 298.82 | 45.15 | 222 | 2104 | 674240 | 62812456 |
| Injection site pain | 271.78 | 45.15 | 119 | 2207 | 129681 | 63357015 |
| Injection site mass | 200.97 | 45.15 | 58 | 2268 | 18598 | 63468098 |
| Hallucination, auditory | 138.58 | 45.15 | 40 | 2286 | 12784 | 63473912 |
| Product administered at inappropriate site | 131.58 | 45.15 | 29 | 2297 | 3120 | 63483576 |
| Syringe issue | 112.03 | 45.15 | 25 | 2301 | 2844 | 63483852 |
| Injection site induration | 105.11 | 45.15 | 30 | 2296 | 9196 | 63477500 |
| Therapeutic response shortened | 89.18 | 45.15 | 28 | 2298 | 11860 | 63474836 |
| Weight increased | 69.85 | 45.15 | 65 | 2261 | 260727 | 63225969 |
| Product administration error | 61.36 | 45.15 | 25 | 2301 | 22372 | 63464324 |
| Paranoia | 53.58 | 45.15 | 19 | 2307 | 11660 | 63475036 |
| Inappropriate schedule of product administration | 53.47 | 45.15 | 38 | 2288 | 103927 | 63382769 |
| Wrong technique in device usage process | 51.49 | 45.15 | 14 | 2312 | 3584 | 63483112 |
| Product physical consistency issue | 49.72 | 45.15 | 10 | 2316 | 689 | 63486007 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Needle issue | 364.78 | 58.59 | 85 | 2396 | 6080 | 34948370 |
| Product administered at inappropriate site | 333.05 | 58.59 | 66 | 2415 | 2170 | 34952280 |
| Injection site pain | 322.70 | 58.59 | 116 | 2365 | 38889 | 34915561 |
| Hallucination, auditory | 197.27 | 58.59 | 60 | 2421 | 11857 | 34942593 |
| Off label use | 163.64 | 58.59 | 172 | 2309 | 419352 | 34535098 |
| Therapeutic response shortened | 151.72 | 58.59 | 44 | 2437 | 7360 | 34947090 |
| Injection site mass | 70.96 | 58.59 | 24 | 2457 | 6602 | 34947848 |
| Syringe issue | 70.58 | 58.59 | 23 | 2458 | 5641 | 34948809 |
| Product dose omission issue | 70.31 | 58.59 | 62 | 2419 | 119649 | 34834801 |
| Underdose | 60.39 | 58.59 | 26 | 2455 | 13754 | 34940696 |
| Wrong technique in device usage process | 59.25 | 58.59 | 15 | 2466 | 1497 | 34952953 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Needle issue | 665.63 | 52.01 | 151 | 4071 | 12917 | 79727249 |
| Injection site pain | 506.08 | 52.01 | 206 | 4016 | 129632 | 79610534 |
| Product administered at inappropriate site | 343.29 | 52.01 | 71 | 4151 | 3894 | 79736272 |
| Off label use | 334.18 | 52.01 | 315 | 3907 | 906900 | 78833266 |
| Hallucination, auditory | 295.57 | 52.01 | 87 | 4135 | 20606 | 79719560 |
| Injection site mass | 237.04 | 52.01 | 73 | 4149 | 20111 | 79720055 |
| Therapeutic response shortened | 188.86 | 52.01 | 58 | 4164 | 15805 | 79724361 |
| Syringe issue | 123.71 | 52.01 | 34 | 4188 | 6264 | 79733902 |
| Injection site induration | 121.49 | 52.01 | 37 | 4185 | 9782 | 79730384 |
| Weight increased | 121.20 | 52.01 | 107 | 4115 | 277279 | 79462887 |
| Product dose omission issue | 113.14 | 52.01 | 98 | 4124 | 247439 | 79492727 |
| Inappropriate schedule of product administration | 91.13 | 52.01 | 67 | 4155 | 133561 | 79606605 |
| Wrong technique in device usage process | 80.27 | 52.01 | 22 | 4200 | 4006 | 79736160 |
| Anxiety | 76.28 | 52.01 | 79 | 4143 | 248433 | 79491733 |
| Paranoia | 72.31 | 52.01 | 30 | 4192 | 19402 | 79720764 |
| Restlessness | 68.61 | 52.01 | 38 | 4184 | 46454 | 79693712 |
| Underdose | 65.69 | 52.01 | 33 | 4189 | 33118 | 79707048 |
| Product physical consistency issue | 65.56 | 52.01 | 14 | 4208 | 891 | 79739275 |
| Soliloquy | 63.62 | 52.01 | 13 | 4209 | 667 | 79739499 |
| Anger | 58.85 | 52.01 | 25 | 4197 | 17137 | 79723029 |
| Incorrect dose administered | 58.06 | 52.01 | 41 | 4181 | 76589 | 79663577 |
| Product administration error | 55.28 | 52.01 | 29 | 4193 | 31817 | 79708349 |
| Hospitalisation | 54.78 | 52.01 | 43 | 4179 | 94193 | 79645973 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
| CHEBI has role | CHEBI:35941 | serotonin agonists |
| CHEBI has role | CHEBI:37955 | H1 receptor antagonists |
| CHEBI has role | CHEBI:50266 | Prodrugs |
| CHEBI has role | CHEBI:65191 | atypical antipsychotic agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.84 | Basic |
| pKa2 | 0.67 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10112903 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8796276 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10112903 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8796276 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10112903 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8796276 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10112903 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8796276 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 675MG/2.4ML | ARISTADA INITIO KIT | ALKERMES INC | N209830 | June 29, 2018 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10112903 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 675MG/2.4ML | ARISTADA INITIO KIT | ALKERMES INC | N209830 | June 29, 2018 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8796276 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10226458 | March 19, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10226458 | March 19, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10226458 | March 19, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10226458 | March 19, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9034867 | Nov. 7, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9034867 | Nov. 7, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9034867 | Nov. 7, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9034867 | Nov. 7, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11097006 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9193685 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11097006 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9193685 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11097006 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9193685 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11097006 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9193685 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10238651 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10813928 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11406632 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9452131 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10238651 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10813928 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11406632 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9452131 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10238651 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10813928 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11406632 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9452131 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10238651 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10813928 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11406632 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9452131 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 675MG/2.4ML | ARISTADA INITIO KIT | ALKERMES INC | N209830 | June 29, 2018 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10849894 | Aug. 17, 2035 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11273158 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11273158 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11273158 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11273158 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 675MG/2.4ML | ARISTADA INITIO KIT | ALKERMES INC | N209830 | June 29, 2018 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11273158 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | PARTIAL AGONIST | Ki | 9.47 | DRUG LABEL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 1A | GPCR | PARTIAL AGONIST | Ki | 8.77 | DRUG LABEL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 8.47 | DRUG LABEL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 6.10 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 7.41 | DRUG LABEL | |||||
| D(3) dopamine receptor | GPCR | Ki | 9.10 | DRUG LABEL | |||||
| Histamine H1 receptor | GPCR | Ki | 7.22 | DRUG LABEL | |||||
| D(4) dopamine receptor | GPCR | Ki | 7.36 | DRUG LABEL | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 7.82 | DRUG LABEL | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | AGONIST | Ki | 7.20 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2A | GPCR | AGONIST | Ki | 7.70 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 7 | GPCR | AGONIST | Ki | 7.80 | IUPHAR | ||||
| D(4) dopamine receptor | GPCR | ANTAGONIST | Ki | 7.30 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 6 | GPCR | AGONIST | Ki | 6.80 | IUPHAR | ||||
| D(2) dopamine receptor | GPCR | AGONIST | Ki | 9.70 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| B786J7A343 | UNII |
| D10364 | KEGG_DRUG |
| 4034891 | VANDF |
| C4056439 | UMLSCUI |
| CHEBI:90930 | CHEBI |
| CHEMBL2219425 | ChEMBL_ID |
| 49831411 | PUBCHEM_CID |
| DB14185 | DRUGBANK_ID |
| C000603935 | MESH_SUPPLEMENTAL_RECORD_UI |
| 1673265 | RXNORM |
| 236432 | MMSL |
| 31226 | MMSL |
| 016489 | NDDF |
| 017628 | NDDF |
| 715182007 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-401 | INJECTION, SUSPENSION, EXTENDED RELEASE | 441 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-401 | INJECTION, SUSPENSION, EXTENDED RELEASE | 441 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-402 | INJECTION, SUSPENSION, EXTENDED RELEASE | 662 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-402 | INJECTION, SUSPENSION, EXTENDED RELEASE | 662 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-403 | INJECTION, SUSPENSION, EXTENDED RELEASE | 882 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-403 | INJECTION, SUSPENSION, EXTENDED RELEASE | 882 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-404 | INJECTION, SUSPENSION, EXTENDED RELEASE | 1064 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-404 | INJECTION, SUSPENSION, EXTENDED RELEASE | 1064 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA INITIO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-500 | INJECTION, SUSPENSION, EXTENDED RELEASE | 675 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA INITIO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-500 | INJECTION, SUSPENSION, EXTENDED RELEASE | 675 mg | INTRAMUSCULAR | NDA | 29 sections |